NEOGENOMICS INC — Director's Dealing 2021

Jul 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-07-05

Reporting Person: Wallar Gina M (President, Pharma Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-05	Common Stock	A	1896	—	Acquired	6013	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-05	Stock Option (Right to Buy)	$43.95	A	10126	Acquired	2028-07-05	Common Stock (10126.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$9.22	2023-04-19	Common Stock (6667.0)	6667	Direct
Stock Option (Right to Buy)	$13.87	2023-12-12	Common Stock (8334.0)	8334	Direct
Stock Option (Right to Buy)	$20.83	2026-05-01	Common Stock (7153.0)	7153	Direct
Stock Option (Right to Buy)	$27.34	2027-05-01	Common Stock (7879.0)	7879	Direct
Stock Option (Right to Buy)	$48.99	2028-05-01	Common Stock (8595.0)	8595	Direct

Footnotes

F1: On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.

F2: On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F3: On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F4: On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F5: On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F6: On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date.